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Abstract 
Purpose: Cystine knot (knottin) peptides, engineered to bind with high affinity to integrin 
receptors, have shown promise as molecular imaging agents in living subjects. The aim of the 
current study was to evaluate tumor uptake and in vivo biodistribution of 
18F-labeled knottins 
in a U87MG glioblastoma model.  
Procedures: Engineered knottin mutants 2.5D and 2.5F were synthesized using solid phase 
peptide  synthesis  and  were  folded  in vitro,  followed  by  radiolabeling  with  4-nitrophenyl 
2-
18F-fluoropropionate (
18F-NFP). The resulting probes, 
18F-FP-2.5D and 
18F-FP-2.5F, were 
evaluated in nude mice bearing U87MG tumor xenografts using microPET and biodistribution 
studies. 
Results: MicroPET imaging studies with 
18F-FP-2.5D and 
18F-FP-2.5F demonstrated high tumor 
uptake in U87MG xenograft mouse models. The probes exhibited rapid clearance from the 
blood and kidneys, thus leading to excellent tumor-to-normal tissue contrast. Specificity 
studies  confirmed  that 
18F-FP-2.5D  and 
18F-FP-2.5F  had  reduced  tumor  uptake  when 
co-injected with a large excess of the peptidomimetic c(RGDyK) as a blocking agent.  
Conclusions: 
18F-FP-2.5D and 
18F-FP-2.5F showed reduced gallbladder uptake compared with 
previously published 
18F-FB-2.5D. 
18F-FP-2.5D and 
18F-FP-2.5F enabled integrin-specific PET 
imaging of U87MG tumors with good imaging contrasts. 
18F-FP-2.5D demonstrated more 
desirable pharmacokinetics compared to 
18F-FP-2.5F, and thus has greater potential for clinical 
translation. 
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Introduction 
Angiogenesis, the formation of new blood ves-
sels from preexisting vasculature, plays a critical role 
in tumor growth and metastasis [1-2]. To grow larger 
than  1–2  mm,  a  tumor  needs  sufficient  blood  flow, 
which provides oxygen and nutrients [3-4]. Integrins 
are a family of heterodimeric transmembrane recep-
tors that are involved in multiple steps of tumor an-
giogenesis and metastasis. In particular, overexpres-
sion of integrins αvβ3, αvβ5, and α5β1 is associated with 
malignancy and has been shown to play various roles 
in tumor growth and metastasis [5-8]. Thus, integrin 
receptors have been attractive targets for developing 
molecular  probes  for  non-invasive  tumor  imaging 
using  different  modalities  including  magnetic  reso-
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nance imaging (MRI) [9], ultrasound [10-12], optical 
imaging [13-15], positron emission tomography (PET) 
[5, 16-18], and single-photon emission computed to-
mography (SPECT) [19-20]. 
Among the ligands that bind integrin receptors, 
arginine-glycine-aspartic acid (RGD)-containing pep-
tides  have  been  well  validated  for  tumor  imaging 
applications  [21-22].  Radiofluorinated  RGD  probes 
such as  18F-AH111585 and  18F-Galacto-RGD are cur-
rently  undergoing  clinical  studies  in  humans  [16, 
23-25]. In order to achieve higher tumor uptake, and 
better  tumor-to-normal  tissue  contrasts,  continued 
efforts to modify RGD-containing ligands remain an 
active area of research. 
Cystine knots (also known as knottins) are small 
polypeptides  with  a  common  disulfide-bonded 
framework  in  which  one  disulfide  bond  threads 
through a macrocycle created by two other disulfide 
bonds  and  their  connecting  backbone  segments 
[26-27], as illustrated in Figure 1A. As a result, knot-
tins  have  a  high  degree  of  thermal  and  proteolytic 
stability and thus provide a valuable framework for 
development of targeting agents for in vivo applica-
tions [28-31]. Furthermore, the relatively small size of 
knottins (~30-50 amino acids) makes them accessible 
by standard solid-phase peptide synthesis, and would 
result in fast blood clearance, which is desirable for 
molecular imaging applications.  
Previously,  high  affinity  integrin  binding  was 
conferred  upon  Ecballium elaterium  trypsin  inhibitor 
(EETI-II) using yeast surface display [32]. The 6-amino 
acid trypsin binding loop  (PRILMR) of EETI-II was 
rationally  substituted  with  an  11-amino-acid  loop 
containing the RGD motif, and combinatorial meth-
ods were used to identify knottin mutants 2.5D and 
2.5F, which bind to αvβ3/αvβ5 or αvβ3/αvβ5/α5β1 in-
tegrins,  respectively,  with  high  (low  nM)  affinity 
[32-33]. The peptide sequences of knottins 2.5D and 
2.5F  are  shown  in  Figure  1B.  Subsequently, 
64Cu-labeled knottins were evaluated in mice bearing 
integrin-expressing U87MG glioblastoma xenografts, 
and  microPET  imaging  and  biodistribution  studies 
showed  rapid  and  high  tumor  accumulation,  fast 
clearance  from  blood  and  normal  organs,  and  low 
uptake in kidney and liver [33]. Overall, these studies 
demonstrated that engineered knottins are promising 
probes for molecular imaging applications.  
 
 
 
 
Figure 1 Schematic and sequences of knottin peptides. (A) Cartoon representation of a radiofluorinated knottin peptide scaffold. The 
imaging label 18F-NFP was site-specifically conjugated to the N-terminus of the knottin. (B) Amino acid sequences of knottin peptides 2.5D 
and 2.5F with disulfide bonds between Cys1-Cys4, Cys2-Cy5, and Cys3-Cys6. (C) Synthetic scheme for 18F-NFP synthon and knottin 
radiofluorination.  
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The physical properties of 18F (t½: 110 min, emits 
β+ particles at an energy of 635 keV, 99% abundant) 
complement the high target binding affinity and rapid 
blood  clearance  of  knottin  peptides.  Previously,  we 
radiolabeled  the  knottin  2.5D  with  18F  via  the 
N-terminus  of  the  peptide  using 
N-succinimidyl-4-18F-fluorobenzoate  (18F-SFB),  and 
showed that this conjugate, 18F-FB-2.5D, could be used 
to image mice bearing U87MG tumor xenografts with 
good  tumor-to-normal  tissue  contrast  [34].  To  im-
prove knottin-based probes for PET imaging and fa-
cilitate their clinical translation, we evaluated the use 
of  an  alternative  18F  precursor,  4-nitrophenyl 
2-18F-fluoropropionate  (18F-NFP),  which  has  shown 
enhanced metabolic stability and reduced hydropho-
bicity  [16,  35-36].  The  resulting  radio  probes, 
18F-FP-2.5D and 18F-FP-2.5F were evaluated for tumor 
uptake and tissue biodistribution in nude mice bear-
ing U87MG tumor xenografts for comparison to our 
previous study.  
Experimental Section 
All commercially available materials were used 
as  provided  unless  noted.  All 
9-fluorenylmethyloxycarbonyl  (Fmoc)  protected 
amino  acids  were  purchased  from  Novabio-
chem/EMD Chemicals Inc (La Jolla, CA) or CS Bio 
(Menlo  Park,  CA).  125I-labeled  echistatin  was  pur-
chased from GE Healthcare Life Sciences (Piscataway, 
NJ). All other chemicals were purchased from Fisher 
Scientific (Fair Lawn, NJ) unless otherwise specified. 
The  U87MG  human  glioblastoma  cell  line  was  ob-
tained from American Type Culture Collection (Ma-
nassas,  VA).  Nude  mice  (nu/nu)  were  purchased 
from  Charles  River  Laboratory  (Wilmington,  MA). 
Semi-preparative  reversed-phase  high  performance 
liquid  chromatography  (RP-HPLC),  using  a  Vydac 
protein and peptide column (218TP510; 5µm, 250 × 10 
mm),  was  performed  on  a  Dionex  680  chromatog-
raphy system with a UVD 170U absorbance detector 
and  model  105S  single-channel  radiation  detector 
(Carroll  &  Ramsey  Associates).  The  recorded  data 
were  processed  using  Chromeleon  version  7.1  soft-
ware.  With  a  flow  rate  of  5.0  mL/min,  the  mobile 
phase  was  changed  from  95%  solvent  A  [0.1%  tri-
fluoroacetic acid (TFA) in water] and 5% B [0.1% TFA 
in acetonitrile (MeCN)] (0–2 min) to 35% solvent A 
and 65% solvent B at 32 min. Analytical scale HPLC 
used the same gradient system except that the flow 
rate was 1.0 mL/min with a Vydac protein and pep-
tide column (218TP510; 5 µm, 250 × 4.6 mm). UV ab-
sorbance was monitored at 218 nm and the identifica-
tion  of  the  peptides  was  confirmed  based  on  UV 
spectrum acquired using a photodiode array detector. 
Instrumentation  used  for  matrix-assisted  laser  de-
sorption/ionization time of flight mass spectrometry 
(MALDI-TOF-MS)  is  the  same  as  described  in  our 
previous publication [37]. 
Chemistry and Radiochemistry Peptides corre-
sponding to the sequence of 2.5D and 2.5F were syn-
thesized  on  a  CS  Bio  CS036  Peptide  Synthesizer 
(Menlo Park, CA) using Fmoc-based solid phase pep-
tide synthesis. Briefly, Rink amide resin was swollen 
in N,N-dimethylformamide (DMF) for 30 min. Fmoc 
groups were removed with 20% piperidine in DMF. 
Aliquots of amino acids (1 mmol) were activated in a 
solution  containing  1  mmol  hydroxybenzotriazole 
(HOBt) and 0.5 M diisopropylcarbodiimide (DIC) in 
DMF.  Following  synthesis,  side-chain  deprotection 
and  resin  cleavage  were  achieved  by  addition  of  a 
94:2.5:2.5:1 (v/v) mixture of TFA/triisopropylsilane/ 
ethanedithiol/water for 2 h at room temperature. The 
crude product was precipitated with cold anhydrous 
ether, and purified using semi-preparative RP-HPLC. 
Peptide  purity  was  analyzed  by  analytical  scale 
RP-HPLC. 
Large scale folding reactions were performed by 
incubating the linear peptide with 4 M guanidine, 10 
mM reduced glutathione, 2 mM oxidized glutathione, 
and 0.5 M dimethyl sulfoxide (DMSO) at pH 7.5. The 
correctly folded peptide was separated from unfolded 
and  partly  folded  peptides  by  RP-HPLC,  where  it 
appeared  as  a  single  peak  with  a  shorter  retention 
time than that of unfolded or misfolded precursors. 
Following purification, folded peptides 2.5D and 2.5F 
were  lyophilized  and  stored  at  room  temperature 
prior  to  use.  Peptide  purity  and  molecular  masses 
were  determined  by  analytical  scale  HPLC  and 
MALDI-TOF-MS, respectively.  
The  synthesis  of  4-nitrophenyl 
2-fluoropropionate (19F-NFP) is briefly described be-
low. Bis(4-nitrophenyl) carbonate (15.2 mg, 50.0 µmol 
in  20  µL  of  diisopropylethylamine  (DIPEA))  was 
added to a solution of 2-fluoropropionic acid (5.0 mg, 
54.3 µmol in 200 µL of DMF). After incubating at 60 °C 
for  3  h,  the  reaction  mixture  was  cooled  to  room 
temperature  and  diluted  with  1  mL  5%  acetic  acid 
solution.  The  product  19F-NFP  was  isolated  by 
semi-preparative HPLC. The collected fractions were 
combined  and  the  solvent  was  removed  under  re-
duced pressure. The product was obtained as white 
powder (5.9 mg, 56%). ESI-MS: m/z 213.1 [M]+;  1H 
NMR (CDCl3, 300 MHz): δ = 8.24 (d, J = 9.0 Hz, 2H), 
7.27 (d, J = 9.0 Hz, 2H), 5.21 (m, 1H), 1.70 (dd, J = 6.8 
Hz, 23.4 Hz, 3H). 13C NMR (CDCl3, 75 MHz): δ = 18.9 
(d, J = 22.5 Hz), 86.0 (d, J = 184.0 Hz), 122.9, 126.0, 
146.4, 155.2, 168.5.  
19F-NFP  labeled  2.5D  and  2.5F  (19F-FP-2.5D, Theranostics 2011, 1 
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19F-FP-2.5F)  were  prepared  as  reference  standards. 
Briefly, 2.5D or 2.5F (0.5 mg, 0.15 mol in 400 L of 
DMSO) was mixed with 19F-NFP (0.3 mg, 1.5 mol in 
100 L of DMSO and 10 L of DIPEA) and reacted for 
1  h  at  room  temperature.  The  resulting  conjugates, 
19F-FP-2.5D  and  19F-FP-2.5F  were  then  purified  by 
semi-preparative  HPLC.  Fractions  containing  the 
product were collected and lyophilized. The molecu-
lar masses of  19F-FP-2.5D and  19F-FP-2.5F were con-
firmed  by  MALDI-TOF-MS.  Folded  peptide  2.5D: 
m/z = 3244.0 for [MH]+ (C129H189N40O47S6, calculated 
[MH]+  =  3244.5).  Retention  time  on  analytical  scale 
HPLC is 16.2 min; Folded peptide 2.5F: m/z = 3292.1 
for  [MH]+  (C131H201N42O46S6,  calculated  [MH]+  = 
3292.6). Retention time: 15.2 min; 19F-FP-2.5D: m/z = 
3317.5 for [MH]+ (C132H193FN40O48S6, calculated [MH]+ 
= 3317.4). Retention time: 17.5 min;  19F-FP-2.5F: m/z 
3364.9 for [MH]+ (C134H203FN42O47S6, calculated [MH]+ 
= 3365.3). Retention time: 18.3 min. 
18F-NFP was prepared and used for knottin ra-
diolabeling based on a previously reported procedure 
(Figure 1C) [38].  18F-NFP (specific activity of 40–100 
GBq/mol  at  the  end  of  synthesis,  in  100  L  of 
DMSO) was added to the 2.5D or 2.5F peptide (100 g) 
and 10 L of DIPEA and reacted for 20 min at 60 °C. 
After adding 1 mL of water containing 50 L of TFA 
to quench the reaction, the resulting conjugates were 
purified  by  semi-preparative  HPLC  using  the  same 
elution gradient as described for 19F-FP-knottin puri-
fication. The HPLC fractions containing 18F-FP-2.5D or 
18F-FP-2.5F were collected, combined, and dried with 
a rotary evaporator. Radiolabeled peptides were re-
constituted in PBS and sterilized using a 0.22 m filter 
(Millipore) for in vitro and in vivo experiments. 
Cell  Culture:  U87MG  cells  were  cultured  in 
DMEM  containing  high  glucose  (GIBCO,  Carlsbad, 
CA), and supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin. Cells were ex-
panded in tissue culture dishes and kept in a humidi-
fied  atmosphere  of  5%  CO2  at  37  °C,  with  media 
changes every other day. Confluent monolayers were 
detached with 0.05% Trypsin-EDTA, 0.01M PBS (pH 
7.4)  and  dissociated  into  single-cell  suspensions  for 
further cell culture and experimentation. 
U87MG  Cell  Binding  Assay:  Cell  binding  as-
says were performed as previously described [37, 39]. 
Briefly, 2  105 U87MG cells were incubated with 0.06 
nM 125I-labeled echistatin and varying concentrations 
of peptides (2.5D, 2.5F, 19F-FP-2.5D or 19F-FP-2.5F) in 
integrin binding buffer [25 mM Tris pH 7.4, 150 mM 
NaCl, 2mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, and 
0.1% bovine serum albumin (BSA)] at room tempera-
ture for 3 h. The cell-bound radioactivity remaining 
after  washing  was  measured  by  gamma-counting. 
Half-maximal  inhibitory  concentration  (IC50)  values 
were  determined  by  nonlinear  regression  using 
GraphPad Prism (GraphPad Software, Inc.). Experi-
ments were performed with quadruplicate samples. 
MicroPET  Imaging:  All  animal  studies  were 
carried out in compliance with Federal and local in-
stitutional regulations for the conduct of animal ex-
perimentation. Approximately 10 × 106 U87MG cells 
were suspended in 100 µL of PBS and subcutaneously 
implanted in the right shoulders of nude mice. Tu-
mors were grown to a size of 0.5 cm in diameter (ap-
proximately  2–3  weeks).  MicroPET  scans  were  per-
formed  on  a  microPET  R4  rodent  model  scanner 
(Concorde  Microsystems  Inc.).  The  scanner  has  a 
computer-controlled bed and 10.8-cm transaxial and 
8-cm axial fields of view (FOVs). It has no septa and 
operates  exclusively  in  the  3-dimensional  (3D)  list 
mode. Mice bearing U87MG xenografts were injected 
via tail vein with approximately 3.7 MBq (100 μCi) of 
18F-FP-2.5D or 18F-FP-2.5F, with or without 10 mg/kg 
mouse body weight c(RGDyK). At 0.5, 1, and 2 h post 
injection (p.i.) mice were anesthetized with isoflurane 
(5% for induction and 2% for maintenance in 100% 
O2).  With  the  help  of  a  laser  beam  attached  to  the 
scanner, mice were placed in the prone position and 
near  the  center  of  the  field  of  view  of  the  scanner 
where the image resolution and sensitivity is highest. 
Three minute static scans were obtained, and images 
were  reconstructed  by  use  of  a  2-dimensional  or-
dered-subsets  expectation  maximization  (OSEM)  al-
gorithm. No background correction was performed. 
Region of interests (ROIs) were drawn over the tumor 
on decay-corrected whole-body coronal images. The 
maximum counts per pixel per minute were obtained 
from the ROI and converted to counts per milliliter 
per minute by using a calibration constant. Based on 
the assumption of a tissue density of 1 g/ml, ROIs 
were converted to counts per gram per min. The per-
cent  injected  dose  per  gram  of  tissue  (%ID/g)  was 
determined by dividing counts per gram per minute 
by injected dose. No attenuation correction was per-
formed. 
Animal  Biodistribution  Studies:  For  biodistri-
bution studies, nude mice bearing U87MG xenografts 
(n = 3 for each group) were injected via tail vein with 
approximately  3.7  MBq  (100  Ci)  of  18F-FP-2.5D  or 
18F-FP-2.5F, with or without 10 mg/kg mouse body 
weight c(RGDyK). Mice were sacrificed at 2 h p.i., and 
tumor and normal tissues of interest were removed 
and weighed, and their radioactivity was measured in 
a  gamma-counter.  The  radioactivity  uptake  in  the 
tumor and normal tissues was expressed as % ID/g. 
Statistical Method: Statistical analysis was per-
formed using the Student's t-test for unpaired data. A Theranostics 2011, 1 
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95%  confidence  level  was  chosen  to  determine  the 
significance  between  groups,  with  P  <  0.05  being 
designated as significantly different.  
Results 
Chemistry  and  Radiochemistry:  Peptides 2.5D 
and  2.5F  were  synthesized  via  solid  phase  peptide 
synthesis, followed by oxidative folding with a mix-
ture  of  glutathione  and  DMSO.  The  final  products 
were  purified  by  semi-preparative  RP-HPLC  to 
achieve greater than 95% purity. Non-radioactive 19F 
analogs  were  used  as  standards  for  radiosynthesis 
and  for  cell  binding  assays.  19F-FP-2.5D  and 
19F-FP-2.5F  were  prepared  by  direct  conjugation  of 
19F-NFP to knottin peptides 2.5D or 2.5F with yields of 
92% and 95%, respectively. Product purities of greater 
than 95% were achieved as determined by analytical 
scale HPLC. MALDI-TOF-MS confirmed correct mo-
lecular masses for all peptides used in this study.  
The  total  synthesis  time  for  18F-NFP  was  ap-
proximately 100 min using a modified GE synthetic 
module  (TRACERlab  FXFN)  with  decay  corrected 
yields of 67 ± 11% (n = 10, Figure 1C) [36, 38]. The 
decay-corrected  radiochemical  yields  of  18F-FP-2.5D 
and  18F-FP-2.5F based on  18F-NFP  were 12.0 ± 2.7% 
and 10.5 ± 1.8% (n = 4), respectively. The radiochem-
ical  purities  of  18F-FP-2.5D  and  18F-FP-2.5F  were 
greater than 99% according to analytical scale HPLC. 
The  specific  radioactivity  of  18F-FP-2.5D  and 
18F-FP-2.5F was estimated to be 20–40 GBq/µmol at 
the end of synthesis.  
 
 
Figure  2 Competition binding of  125I-echistatin to integrin re-
ceptors expressed on U87MG cells by 2.5D, 2.5F, 19F-FP-2.5D, or 
19F-FP-2.5F.  Results  expressed  as  percentage  of  125I-echistatin 
binding are the mean of quadruplicate measurements  standard 
deviation. [M] = peptide molar concentration 
 
In Vitro Cell Receptor-Binding Assay: Integrin 
positive U87MG human glioblastoma cells were used 
for  binding  studies.  Binding  affinities  of  2.5D,  2.5F, 
19F-FP-2.5D  and  19F-FP-2.5F  were  determined  by 
competitive  displacement  of  125I-echistatin,  a  potent 
integrin binder, from U87MG cells. All peptides in-
hibited the binding of 125I-echistatin to U87MG cells in 
a  concentration-dependent  manner.  The  IC50  values 
for 19F-FP-2.5D and 19F-FP-2.5F were 7.4 ± 1.9 and 7.5 ± 
1.3 nM, respectively (n = 4) (Figure 2). Comparison of 
binding values to unlabeled 2.5D and 2.5F (IC50 values 
= 6.9 ± 1.4 and 6.1 ± 1.6 nM, respectively) showed that 
fluoropropionate  conjugation  did  not  interfere  with 
integrin receptor binding. 
 
 
Figure 3 (A) and (C) Coronal microPET images of U87MG tu-
mor-bearing mice at 0.5, 1, and 2 h post injection of approximately 
3.7 MBq (100 µCi) of 18F-FP-2.5D or 18F-FP-2.5F, respectively. (B) 
and (D) Coronal microPET images of U87MG tumor-bearing mice 
at 0.5, 1, and 2 h after co-injection of approximately 3.7 MBq (100 
µCi) of 18F-FP-2.5D and 18F-FP-2.5F with 10 mg c(RGDyK) per kg 
mouse body weight, respectively. Red arrows indicate tumors. 
 
MicroPET  Imaging  Study:  Static  microPET 
scans were performed on U87MG tumor-bearing mice 
and representative decay-corrected coronal images at 
0.5, 1, and 2 h after tail vein injection of 18F-FP-2.5D or 
18F-FP-2.5F  are  shown  in  Figure  3  (n  =  3  for  each Theranostics 2011, 1 
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group).  U87MG  tumors  were  clearly  visualized,  as 
both tracers produced excellent tumor-to-background 
contrast. MicroPET quantification of tumors and other 
organs was obtained from ROI analysis and the re-
sults at 0.5, 1, and 2 h p.i. are shown in Figure 4A and 
B. No significant difference in tumor uptake between 
these two probes was observed at each time point (P > 
0.05). For 18F-FP-2.5D, tumor uptake was 3.30 ± 1.08, 
2.86 ± 1.11, and 2.37 ± 1.13 %ID/g at 0.5, 1, and 2 h p.i., 
respectively. For 18F-FP-2.5F, tumor uptake was 3.74 ± 
0.88, 3.60 ± 0.25, and 1.71 ± 0.37 % ID/g at 0.5, 1, and 2 
h p.i., respectively. Both probes were cleared rapidly 
from the blood, and moderate to low renal retention 
was observed (4.24 ± 1.94, 2.81 ± 1.42, and 2.68 ± 2.90 
%ID/g for  18F-FP-2.5D at 0.5, 1, and 2 h p.i.; 13.39 ± 
1.15, 5.25 ± 0.65, and 2.51 ± 0.16 %ID/g for 18F-FP-2.5F 
at 0.5, 1, and 2 h p.i.). Interestingly, liver uptake of 
18F-FP-2.5F was significantly higher than  18F-FP-2.5D 
at 0.5 h p.i., (P < 0.05), while no significant difference 
was observed at 1 h and 2 h p.i. Nonspecific uptake in 
the muscle was very low for both probes (0.51 ± 0.30 
%ID/g  and  0.44  ±  0.08  %ID/g  for  18F-FP-2.5D  and 
18F-FP-2.5F at 2 h p.i., respectively). Gallbladder up-
take of 18F-FP-2.5D and 18F-FP-2.5F was 0.86 ± 0.33 and 
1.08 ± 0.41 %ID/g at 2 h p.i., respectively; these values 
were  similar  to  background  muscle  uptake  level. 
Tumor-to-normal tissues ratios of both probes at 0.5, 
1, and 2 h were calculated and are shown in Figure 
4C. At 0.5 h p.i., 18F-FP-2.5D had higher tumor to liver, 
kidneys, and muscle ratios than those of 18F-FP-2.5F (P 
< 0.05). This is consistent with the better tumor image 
quality of 18F-FP-2.5D compared to 18F-FP-2.5F at early 
time points (0.5 and 1 h p.i.), shown in Figure 3A and 
C.  
 
Figure 4 (A) and (B) MicroPET quantification results, expressed as %ID/g, in tumor and organs of U87MG xenograft models after 
intravenous injection of ~3.7 MBq 18F-FP-2.5D or 18F-FP-2.5F, respectively. (C) Tumor/nontumor (T/NT) ratios at 0.5, 1 and 2 h p.i. were 
calculated from A and B. GB = Gallbladder. 
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Figure 5 Biodistribution of 18F-FP-2.5D or 18F-FP-2.5F in U87MG tumor-bearing mice at 2 h after injection with or without co-injection 
of 10 mg/kg of c(RGDyK) as a blocking agent. Data are expressed as %ID/g ± SD (n = 3 per group).  
 
The integrin targeting specificity of both probes 
was  demonstrated  by  co-injection  of  an  excess  of 
c(RGDyK) as a blocking agent. Figure 3B and D show 
the microPET images of 18F-FP-2.5D and 18F-FP-2.5F at 
0.5, 1, and 2 h p.i. with co-injection of c(RGDyK). The 
corresponding  microPET  quantification  results  are 
shown in Figure 4. Coinjection of c(RGDyK) resulted 
in  significant  decreases  in  tumor  uptake  for  both 
18F-FP-2.5D (3.91 ± 0.15 %ID/g without blocking vs. 
1.96  ±  0.07  %ID/g  with  blocking,  P  <  0.05)  and 
18F-FP-2.5F (3.83 ± 0.51 %ID/g  without blocking  vs. 
1.90 ± 0.21 %ID/g with blocking, P < 0.05). 
Biodistribution Studies:  To validate microPET 
imaging  experiments,  biodistribution  studies  of 
18F-FP-2.5D and 18F-FP-2.5F were performed at 2 h p.i. 
in U87MG xenograft models. Probe uptake in tumors 
and other major organs was calculated and is shown 
in Figure 5. No significant differences were observed 
compared to microPET image quantification. In these 
studies, the in vivo tumor targeting specificity of the 
probes  was  further  confirmed  by  co-injection  of  an 
excess of c(RGDyK) blocking agent. A significant de-
crease  in  tumor  uptake  was  observed  for  both 
18F-FP-2.5D (1.92 ± 0.65 %ID/g vs. 1.06 ± 0.10 %ID/g, 
P < 0.05) and 18F-FP-2.5F (2.24 ± 0.60 %ID/g vs. 1.25 ± 
0.10  %ID/g,  P  <  0.05)  upon  co-injection  with 
c(RGDyK). 
Discussion  
Probe  development  is  a  central  theme  in  can-
cer-specific molecular imaging applications. Histori-
cally, it has been challenging and time consuming to 
develop  probes  that  bind  tumor-related  receptors 
with high affinity and specificity [40-42]. Numerous 
efforts have sought to generalize binder development 
using  a  variety  of  molecular  platforms.  Recently, 
small protein scaffolds have become robust starting 
points for molecular probe development [39, 43-44]. 
Knottins,  which  are  generally  3–5  kDa  in  size,  are 
highly  stable  scaffolds  that  have  been  shown  to  be 
amenable to rational and combinatorial engineering. 
Moreover, knottin engineering methods are maturing 
as  new  binders  are  being  developed  based  on  this 
versatile  framework  [30,  45].  Recently,  high-affinity 
integrin-binding knottins were successfully identified 
by  yeast  display  technology  [32-33].  Radiolabeled Theranostics 2011, 1 
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knottins,  using  64Cu  or  18F  for  PET  imaging,  have 
shown great promise for imaging integrin expression 
in mouse tumor models [31, 44, 46]. 
In this study, we evaluated 18F-FP-labeled knot-
tin 2.5D and 2.5F and explored potential advantages 
over  18F-FB analogs, including effects on tumor up-
take and retention and uptake in non-target organs. 
18F-fluoropropionate was chosen because it has rela-
tively higher in vivo metabolic stability compared to 
18F-fluorobenzoate, as indicated by a high percentage 
of intact 18F-FP-labeled probe in a metabolite analysis 
[38]. Moreover,  18F-fluoropropionate is a less hydro-
phobic tag than that of  18F-fluorobenzoate. Methods 
for radiosynthesis of 18F-NFP have also been well es-
tablished [38, 47-48]. Importantly,  18F-NFP is practi-
cally  the  smallest  18F-radiolabeling  group  for  pep-
tides, and is currently being used in clinical trials in 
human subjects [16, 23, 35].  
Figure 4A and B show the results of microPET 
image  quantification  of  18F-FP-2.5D  and  18F-FP-2.5F, 
which exhibit rapid tumor targeting and good tumor 
retention.  Both  probes  exhibited  maximum  tumor 
uptake at 0.5 h p.i., and sustained tumor accumulation 
was observed. For example, at 1 and 2 h p.i., tumor 
uptake values were 2.86 ± 1.11 and 2.37 ± 1.13 %ID/g 
for 18F-FP-2.5D, and 3.60 ± 0.25 and 1.71 ± 0.37 %ID/g 
for 18F-FP-2.5F, respectively. Comparatively, the pre-
viously published knottin,  18F-FB-2.5D demonstrated 
lower tumor uptake of 1.46 ± 0.35 %ID/g at 1 h p.i. 
[34]. Furthermore, gallbladder uptake was lower for 
18F-FP-2.5D (1.17 ± 0.47 %ID/g at 1 h p.i.), compared 
to  18F-FB-2.5D  (2.82  ± 1.31  %ID/g),  which  could  be 
due to lower in vivo stability of  18F-FB compared to 
18F-FP. For example, in a previous study, high in vivo 
stability was reported for a 18F-FP labeled RGD dimer; 
more  than  95%  of  the  18F-labeled  RGD  dimer  was 
shown  to  be  intact  at  2  h  p.i.  [38].  Importantly, 
18F-FP-2.5D had higher tumor-to-normal tissue ratios 
than 18F-FB-2.5D, thus the 18F-FP label resulted in im-
proved  imaging  quality.  Tumor-to-organ  ratios  for 
liver, kidneys, lungs, and gallbladder were 2.56 ± 0.55, 
0.83 ± 0.28, 3.74 ± 0.70, and 2.53± 0.39, respectively, at 
0.5 h p.i. for 18F-FP-2.5D. In comparison, ratios for the 
same organs for  18F-FB-2.5D were 1.97 ± 0.75, 0.50 ± 
0.16, 2.03 ± 0.40, and 0.71 ± 0.32, respectively (Figure 
4C). Collectively, these results highlight advantages of 
using a FP prosthetic group versus FB for knottin ra-
diolabeling and in vivo imaging.  
The  IC50  values  of  knottin  2.5D  and  2.5F  indi-
cated  higher  affinity  integrin  binding  compared  to 
that of a cyclic RGD pentapeptide (c(RGDyK)) pub-
lished in the literature [49]; however, the tumor up-
take for these probes were similar. For example, the 
U87MG  tumor  uptake  of  18F-FB  labeled  c(RGDyK) 
was 2.56 ± 0.12 %ID/g [50], compared to tumor up-
take values of 2.24 ± 0.60 %ID/g for 18F-FP-2.5F at 2 h 
p.i. in the biodistribution study. These results indicate 
that the in vivo performance of a peptide-based mo-
lecular imaging probe depends on not only binding 
affinity, but other parameters such as charge, size, or 
hydrophobicity.  
64Cu-labeled knottin 2.5D and 2.5F analogs had 
similar  tumor  and  normal  tissue  uptake,  which  re-
sulted  in  comparable  microPET  contrast.  However, 
different contrasts were observed for 18F-FP-2.5D and 
18F-FP-2.5F  (Figure  3A  and  C).  18F-FP-2.5D  showed 
better  image  quality  compared  to  18F-FP-2.5F  at  0.5 
and 1 h p.i., but at a later time point (2 h p.i.), the tu-
mor-to-muscle ratios for  18F-FP-2.5D and  18F-FP-2.5F 
reached the same level. Despite having similar bind-
ing  affinities,  the  amino  acid  residues  flanking  the 
RGD motif in the engineered integrin binding loops of 
2.5D and 2.5F are very different (Figure 1B), which 
may  have  influenced  their  in  vivo  behavior  in  this 
study. These results further indicate the importance of 
evaluating different radiolabeling methods in order to 
optimize the in vivo performance of protein- or pep-
tide-based imaging probes.  
PET  provides  a  sensitive  technique  to  identify 
and  characterize  disease  in  living  systems.  For  a 
newly-developed PET probe to be successfully trans-
lated into the clinic, it should have high tumor uptake 
with reasonable tumor-to-background ratios in sup-
port  of  clinical  radioisotopes  with  relatively  short 
half-lives, such as 18F. The PET probe should also be 
able to be prepared in high radiochemical yield, pu-
rity,  and  specific  activity.  The  total  radiosynthesis 
time  for  18F-FP-2.5D  and  18F-FP-2.5F  was  approxi-
mately 100 minutes. Furthermore, the  18F-FP labeled 
knottins  developed  here  meet  some  of  these  basic 
criteria such as high labeling yield, high in vivo stabil-
ity, high radiochemical purity and good tumor uptake 
with  high  tumor-to-background  ratios.  Together, 
these results suggest that 18F-FP-2.5D, and potentially 
18F-FP-2.5F,  may  have  clinical  potential  for  integrin 
imaging.  
In  conclusion,  radiolabeled  knottin  peptides, 
18F-FP-2.5D and  18F-FP-2.5F showed integrin-specific 
PET  imaging  of  U87MG  tumors  marked  by  good 
contrast,  fast  tumor  targeting,  rapid  clearance  from 
body and relatively low uptake in normal tissues. The 
18F-FP-labeled knottin mutant 2.5D exhibited higher 
tumor-to-normal  tissue  contrast  compared  to 
18F-FB-2.5D, perhaps due to increased in vivo stability 
of  18F-FP residue. Taken together, these results sug-
gest that 18F-FP-2.5D may perform well in clinical ap-
plications.  Theranostics 2011, 1 
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